Literature DB >> 33767665

Ototoxicity of Non-aminoglycoside Antibiotics.

Leonard P Rybak1, Vickram Ramkumar2, Debashree Mukherjea1.   

Abstract

It is well-known that aminoglycoside antibiotics can cause significant hearing loss and vestibular deficits that have been described in animal studies and in clinical reports. The purpose of this review is to summarize relevant preclinical and clinical publications that discuss the ototoxicity of non-aminoglycoside antibiotics. The major classes of antibiotics other than aminoglycosides that have been associated with hearing loss in animal studies and in patients are discussed in this report. These antibiotics include: capreomycin, a polypeptide antibiotic that has been used to treat patients with drug-resistant tuberculosis, particularly in developing nations; the macrolides, including erythromycin, azithromycin and clarithromycin; and vancomycin. These antibiotics have been associated with ototoxicity, particularly in neonates. It is critical to be aware of the ototoxic potential of these antibiotics since so much attention has been given to the ototoxicity of aminoglycoside antibiotics in the literature.
Copyright © 2021 Rybak, Ramkumar and Mukherjea.

Entities:  

Keywords:  azithromycin; capreomycin; chloramphenicol; clarithromycin; erythromycin; macrolides; ototoxicity; vancomycin

Year:  2021        PMID: 33767665      PMCID: PMC7985331          DOI: 10.3389/fneur.2021.652674

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  96 in total

1.  The effects of chloramphenicol upon the electrical activity of the ear.

Authors:  W C PATTERSON; W L GULICK
Journal:  Ann Otol Rhinol Laryngol       Date:  1963-03       Impact factor: 1.547

2.  Irreversible sensorineural hearing loss due to erythromycin.

Authors:  J Dylewski
Journal:  CMAJ       Date:  1988-08-01       Impact factor: 8.262

3.  Chemical and physical characterization of capreomycin.

Authors:  E B Herr; M O Redstone
Journal:  Ann N Y Acad Sci       Date:  1966-04-20       Impact factor: 5.691

4.  Why monitor peak vancomycin concentrations?

Authors:  N J Saunders
Journal:  Lancet       Date:  1994 Dec 24-31       Impact factor: 79.321

5.  Sensorineural hearing loss as a probable serious adverse drug reaction associated with low-dose oral azithromycin.

Authors:  Paul Mick; Brian D Westerberg
Journal:  J Otolaryngol       Date:  2007-10

6.  Erythromycin ototoxicity.

Authors:  P Thompson; R P Wood; L Bergstrom
Journal:  J Otolaryngol       Date:  1980-02

7.  Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia.

Authors:  D J Swanson; R J Sung; M J Fine; J J Orloff; S Y Chu; V L Yu
Journal:  Am J Med       Date:  1992-01       Impact factor: 4.965

8.  Evaluating Hearing Loss in Patients Undergoing Second Line Anti Tubercular Treatment.

Authors:  Jagram Verma; T Syed Mohammed
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-03-09

9.  Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases.

Authors:  Hui Li; Ding-Hui Liu; Lu-Lu Chen; Qi Zhao; Yan-Zhe Yu; Jing-Jing Ding; Li-Yun Miao; Yong-Long Xiao; Hou-Rong Cai; De-Ping Zhang; Yu-Biao Guo; Can-Mao Xie
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

10.  Ototoxicity of erythromycin in man: electrophysiologic approach.

Authors:  J A Sacristán; M Angeles De Cos; J Soto; F Zurbano; J Pascual; A Tasis; R Valle; C De Pablos
Journal:  Am J Otol       Date:  1993-03
View more
  4 in total

1.  Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit.

Authors:  Bo Zhou; Wenyi Xiong; Ke Bai; Hongxing Dang; Jing Li; Feng Xu; Yue-Qiang Fu; Chengjun Liu
Journal:  Front Pediatr       Date:  2022-06-30       Impact factor: 3.569

2.  Azithromycin-Induced Liver Injury in an Asthma Exacerbation Patient With Autoimmune Features.

Authors:  Richard Liang; Adesh Ramdass
Journal:  Cureus       Date:  2022-05-29

Review 3.  Overcoming Mycobacterium tuberculosis through small molecule inhibitors to break down cell wall synthesis.

Authors:  Wenbin Kuang; Haolin Zhang; Xiao Wang; Peng Yang
Journal:  Acta Pharm Sin B       Date:  2022-04-27       Impact factor: 14.903

4.  Putative COVID-19 therapies imatinib, lopinavir, ritonavir, and ivermectin cause hair cell damage: A targeted screen in the zebrafish lateral line.

Authors:  Allison B Coffin; Emily Dale; Emilee Doppenberg; Forrest Fearington; Tamasen Hayward; Jordan Hill; Olivia Molano
Journal:  Front Cell Neurosci       Date:  2022-08-24       Impact factor: 6.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.